<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04718727</url>
  </required_header>
  <id_info>
    <org_study_id>IRB: 17300536</org_study_id>
    <nct_id>NCT04718727</nct_id>
  </id_info>
  <brief_title>Olanzapine for the Prevention of Postoperative Nausea and Vomiting</brief_title>
  <official_title>Olanzapine for the Prevention of Postoperative Nausea and Vomiting After Laparoscopic Surgery in High-risk Patients: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amani Hassan Abdel-Wahab</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nausea and vomiting (PONV) remain a common problem in surgical units. Even after two or three&#xD;
      prophylactic antiemetic interventions, patients with all four of the Apfel risk factors for&#xD;
      PONV have an estimated 30 to 40% chance of suffering PONV. Olanzapine as an antiemetic&#xD;
      represents a new use of an antipsychotic drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim of the Research, to compare the effects of oral 10 and 5 mg Olanzapine for the Prevention&#xD;
      of Postoperative Nausea and Vomiting&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All patients will receive oral 10, 5 mg Olanzapine or placebo one hour preoperative</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>nausea and/or vomiting score</measure>
    <time_frame>first 24 hours postoperative</time_frame>
    <description>the occurrence of nausea and/or vomiting by nausea score</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">206</enrollment>
  <condition>Postoperative Nausea</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients will receive oral placebo tablets one hour preoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive oral 5 mg Olanzapine tablets one hour preoperatively</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive oral 10 mg Olanzapine tablets one hour preoperatively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral Placebo tablets one-hour preoperatively</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg Olanzapine Tablets</intervention_name>
    <description>oral 5 mg Olanzapine tablets one-hour preoperatively</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10 mg Olanzapine Tablets</intervention_name>
    <description>oral 10 mg Olanzapine tablets one-hour preoperatively</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>zyprexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA I and II patients&#xD;
&#xD;
          -  undergoing ambulatory laparoscopic gynecologic surgery with general anesthesia&#xD;
&#xD;
          -  patients have at least two of the four Apfel risk factors for PONV2&#xD;
&#xD;
          -  Lack of history of psychiatric and psychotic illnesses.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ASA III and â‰¥ IV patients&#xD;
&#xD;
          -  Psychological diseases&#xD;
&#xD;
          -  History of chemotherapy&#xD;
&#xD;
          -  have a pre-existing vestibular disorder or history of dizziness or preexisting nausea&#xD;
             or vomiting in the 24 h before surgery, or were being treated with regular antiemetic&#xD;
             therapy including systemic corticosteroids.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amani H Abdel-wahab, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amani H Abdel-wahab, MD</last_name>
    <phone>01004610623</phone>
    <email>amanyabdelwhab@aun.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assiut university hospitals</name>
      <address>
        <city>Assiut</city>
        <state>Assiut Governorate</state>
        <zip>Egypt, 715715</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amany Hassan Abdel-Wahab, lectural</last_name>
      <phone>01004610623</phone>
      <email>Amanihassan1976@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assiut university</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amani H Abdei-wahab, MD</last_name>
      <phone>01004610623</phone>
      <email>amanyabdelwhab@aun.edu.eg</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assiut university</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amani H Abdei-wahab, MD</last_name>
      <phone>01004610623</phone>
      <email>amanyabdelwhab@aun.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 17, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Amani Hassan Abdel-Wahab</investigator_full_name>
    <investigator_title>assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

